MOORESTOWN, N.J., Sept. 28, 2016 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk, today announced the pricing of its initial public offering of 4,300,000 shares of its common stock, at a price of $12.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Tabula Rasa. The shares are expected to begin trading on The NASDAQ Global Market on September 29, 2016, under the symbol “TRHC.” In addition, Tabula Rasa granted the underwriters a 30-day option to purchase up to 645,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. This offering is expected to close on October 4, 2016, subject to customary closing conditions.
Wells Fargo Securities and UBS Investment Bank are acting as joint-book running managers for the offering. Piper Jaffray is also acting as a book-runner, with Baird and Stifel acting as co-managers for the offering.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on September 28, 2016. The offering will be made only by means of a written prospectus forming part of the effective registration statement. A copy of the final prospectus relating to this offering, when available, may be obtained for free by visiting EDGAR on the SEC's website at www.sec.gov, or alternatively, from: Wells Fargo Securities, LLC by mailing: Attention: Equity Syndicate Department, 375 Park Avenue, New York, NY 10152, by email: firstname.lastname@example.org or by Telephone: (800) 326-5897, or from UBS Securities LLC by mailing: Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019 or by Telephone: (888) 827-7275.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.GlobeNewswire
Last updated on: 29/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.